🇺🇸 FDA
Pipeline program

A SINGLE-ARM, OPEN-LABEL, PHASE I STUDY TO DETERMINE THE SAFETY, TOLERABILITY, AND PRELIMINARY EFFICACY OF OBE-CEL IN PARTICIPANTS WITH REFRACTORY PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS

AUTO1-MS1

Phase 1 other active

Quick answer

A SINGLE-ARM, OPEN-LABEL, PHASE I STUDY TO DETERMINE THE SAFETY, TOLERABILITY, AND PRELIMINARY EFFICACY OF OBE-CEL IN PARTICIPANTS WITH REFRACTORY PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS for Refractory Progressive Multiple Sclerosis is a Phase 1 program (other) at Autolus GmbH with 1 ClinicalTrials.gov record(s).

Program details

Company
Autolus GmbH
Indication
Refractory Progressive Multiple Sclerosis
Phase
Phase 1
Modality
other
Status
active

Clinical trials